Get the Stockscreener App
0.7301
2.67%
-0.02
Equillium Inc stock is traded at $0.7301, with a volume of 222.41K.
It is down -2.67% in the last 24 hours and down -15.58% over the past month.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
See More
Previous Close:
$0.7501
Open:
$0.722
24h Volume:
222.41K
Relative Volume:
1.18
Market Cap:
$25.15M
Revenue:
$42.62M
Net Income/Loss:
$-8.32M
P/E Ratio:
-1.3775
EPS:
-0.53
Net Cash Flow:
$-15.77M
1W Performance:
-46.90%
1M Performance:
-15.58%
6M Performance:
-56.28%
1Y Performance:
+46.02%
1-Day Range:
$0.7005
$0.7579
1-Week Range:
$0.68
$1.50
52-Week Range:
$0.45
$3.25
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
Equillium Inc Stock (EQ) Latest News
Equillium says Ono not acquiring itolizumab, stock craters 36% - MSN
Ono says no to Equillium’s itolizumab - The Pharma Letter
Jones Trading Downgrades Equillium (EQ) - MSN
Equillium retains rights to itolizumab after Ono's option expires - Investing.com India
Equillium shares downgraded to hold from buy By Investing.com - Investing.com Canada
Equillium shares downgraded to hold from buy - Investing.com India
Equillium keeps equilibrium in GVHD after Ono no-go - BioWorld Online
Equillium says Ono not acquiring itolizumab, stock craters 36% (NASDAQ:EQ) - Seeking Alpha
Equillium Maintains Rights to Itolizumab Following Ono Partnership - StockTitan
Equillium COO Christine Zedelmayer sells $18,750 in stock - Investing.com
Equillium COO Christine Zedelmayer sells $18,750 in stock By Investing.com - Investing.com Australia
Insider Sale: Sr. Vice President and COO Christine Zedelmayer Se - GuruFocus.com
Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World
Renaissance Technologies LLC Acquires 91,200 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - StockTitan
Equillium CFO Jason Keyes sells $8,100 in company stock By Investing.com - Investing.com South Africa
Equillium CFO Jason Keyes sells $8,100 in company stock - Investing.com India
Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop - Simply Wall St
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Equillium executive sells $32,985 in stock - Investing.com India
Equillium executive sells $32,985 in stock By Investing.com - Investing.com Australia
Equillium collaborates with Vivtex for oral formulation of autoimmune therapy - Yahoo Finance
Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy - ForexTV.com
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - StockTitan
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wall Street analysts’ outlook for Equillium Inc (EQ) - SETE News
Equillium Inc’s Market Journey: Closing Weak at 1.07, Down -0.93 - The Dwinnex
How should investors view Equillium Inc (EQ)? - US Post News
Equillium Inc Inc. (EQ) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference - StockTitan
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26 - Business Wire
Q3 2024 Earnings Forecast for Equillium, Inc. (NASDAQ:EQ) Issued By HC Wainwright - Defense World
Equillium, Inc. (NASDAQ:EQ) Forecasted to Post FY2024 Earnings of $0.62 Per Share - Defense World
Equillium’s (EQ) Buy Rating Reiterated at HC Wainwright - Defense World
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience - Marketscreener.com
Equillium Second Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Equillium (NASDAQ:EQ) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - Defense World
EQEquillium, Inc. Latest Stock News & Market Updates - StockTitan
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates - MSN
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights - StockTitan
Equillium Inc (EQ) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Equillium's itolizumab advances in phase 3 aGVHD trial - Investing.com
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease - StockTitan
Acadian Asset Management LLC Acquires New Holdings in Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium faces delisting risk, Nasdaq warns on bid price - Investing.com India
Equillium faces delisting risk, Nasdaq warns on bid price By Investing.com - Investing.com Canada
Equillium CFO Jason Keyes sells shares worth $8,700 - Investing.com
Equillium reports $33.3 million in cash and investments By Investing.com - Investing.com
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance - StockTitan
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Equillium Inc Stock (EQ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zedelmayer Christine | Sr. Vice President and COO |
Oct 28 '24 |
Sale |
1.25 |
15,000 |
18,750 |
135,246 |
| Tom Penny | Principal Accounting Officer |
Oct 28 '24 |
Sale |
1.25 |
2,835 |
3,544 |
6,533 |
| Tom Penny | Principal Accounting Officer |
Oct 25 '24 |
Sale |
1.25 |
683 |
854 |
9,368 |
| Keyes Jason A | Chief Financial Officer |
Sep 26 '24 |
Sale |
0.81 |
10,000 |
8,100 |
57,720 |
| Tom Penny | Principal Accounting Officer |
Sep 16 '24 |
Sale |
0.85 |
38,806 |
32,985 |
10,051 |
| Keyes Jason A | Chief Financial Officer |
Jul 16 '24 |
Sale |
0.87 |
10,000 |
8,700 |
67,720 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):